| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 22nd December 2020 | Partners L P/Il Bvf | 97,615 | Conversion of derivative | $0.00 | |
| 22nd December 2020 | Partners L P/Il Bvf | 15,166 | Conversion of derivative | $0.00 | |
| 22nd December 2020 | Partners L P/Il Bvf | 509,410 | Conversion of derivative | $0.00 | |
| 22nd December 2020 | Partners L P/Il Bvf | 1,944 | Conversion of derivative | $0.00 | |
| 22nd December 2020 | Partners L P/Il Bvf | 654,215 | Conversion of derivative | $0.00 | |
| 22nd December 2020 | Partners L P/Il Bvf | 11,278 | Conversion of derivative | $0.00 | |
| 15th December 2020 | James R Neal | 26,000 | Exercise of derivative | $5.50 | $143,000.00 |
| 15th December 2020 | James R Neal | 5,706 | Open or private sale | $42.04 | $239,900.21 |
| 15th December 2020 | James R Neal | 20,294 | Open or private sale | $41.15 | $835,098.10 |
| 15th December 2020 | James R Neal | 8,000 | Grant/award etc. | $25.00 | $200,000.00 |
Xoma
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab.
Ticker: XOMA
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 791908
Employees: 10
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Assets, Current: $52 M (-12%)
Property, Plant and Equipment, Net: $22 Th (-35%)
Other Assets, Noncurrent: $215 Th (42%)
Assets: $88 M (-8%)
Long-term Debt, Current Maturities: $8 M (0%)
Accounts Payable, Current: $646 Th (5%)
Liabilities, Current: $11 M (27%)
Long-term Debt, Excluding Current Maturities: $23 M (0%)
Other Liabilities, Noncurrent: $35 Th (-18%)
Liabilities: $49 M (-4%)
Common Stock, Value, Issued: $83 Th (13%)
Common Stock, Shares, Issued: $11 M (12%)
Retained Earnings (Accumulated Deficit): $1 B (0%)
Stockholders' Equity (Parent): $38 M (0%)
Liabilities and Equity: $88 M (-8%)
Revenue: $53 Th (-90%)
Research and Development: $38 Th (-62%)
General and Administrative Expenses: $4 M (-64%)
Operating Income/Loss: $3 M (-64%)
Provision for income taxes: $2 M (1%)
News
XOMA: A Royalty Aggregator To Watch
4th January 2021
XOMA Announces Offering of Series A Cumulative Perpetual Preferred Stock
10th December 2020